Plumbagin protects against glucocorticoid-induced osteoporosis through Nrf-2 pathway

被引:20
|
作者
Zhang, Shuai [1 ]
Li, Dong [2 ]
Yang, Jing-Yan [3 ]
Yan, Ting-Bin [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Orthoped, Jinan 250012, Shandong, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Dept Orthoped, Jinan 250021, Shandong, Peoples R China
[3] Shandong Univ, Hosp 2, Dept Pathol, Jinan 250033, Shandong, Peoples R China
来源
CELL STRESS & CHAPERONES | 2015年 / 20卷 / 04期
关键词
Osteogenesis; Glucocorticoids; Apoptosis; Oxidative stress; ROS; INDUCED OXIDATIVE STRESS; ALKALINE-PHOSPHATASE ACTIVITY; FACTOR-KAPPA-B; OSTEOBLASTIC DIFFERENTIATION; INDUCED APOPTOSIS; ASSAY; INFLAMMATION; OSTEOCYTES; ACTIVATOR; CORTISOL;
D O I
10.1007/s12192-015-0585-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Long-term and high-dose glucocorticoids (GCs) supplementation has been linked to osteoporosis. In this study, we studied the protective role of plumbagin against GC-induced cell damage in MC3T3-E1 cells. The effect of dexamethasone (DEX) and plumbagin on cell viability was determined. DEX showed as IC-50 value of 95 mu M. Further, 10 mu M plumbagin treatment effectively ameliorated DEX-induced cell death by increasing the cell viability to 92 %. A further effect of plumbagin on DEX-induced oxidative stress was determined through reactive oxygen species (ROS) level, lipid peroxide content, and antioxidant status. Nrf-2 nuclear localization was analyzed through immunofluorescence. Protein expression of redox regulator Nrf-2 and their target genes HO-1 and NQO1 and osteogenic markers (OCN, OPN Runx-2) were determined by Western blot. Apoptotic effect was analyzed by mitochondrial membrane potential and caspase activities (3, 8, and 9). The results showed that DEX treatment showed a significant increase in oxidative stress through increased ROS levels and downregulation of cytoprotective antioxidant proteins and antioxidant enzyme activities. Further DEX treatment downregulated the osteogenic markers and upregulated apoptosis through decreased mitochondrial membrane potential and upregulation of caspase activities. Plumbagin treatment significantly reversed the levels of oxidative stress and apoptotic markers and protected against DEX-induced cell damage. Further, plumbagin treatment significantly improved the expression of osteogenic markers compared to DEX treatment. In conclusion, the present study shows that plumbagin offers significant protective role against DEX-induced cellular damage via regulating oxidative stress, apoptosis, and osteogenic markers.
引用
收藏
页码:621 / 629
页数:9
相关论文
共 50 条
  • [21] Glucocorticoid-Induced Osteoporosis
    Buckley, Lenore
    Humphrey, Mary B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2547 - 2556
  • [22] Glucocorticoid-Induced Osteoporosis
    Humphrey, Mary B.
    Buckley, Lenore
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (14): : 1378 - 1379
  • [23] Glucocorticoid-induced osteoporosis
    Manelli, F
    Giustina, A
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2000, 11 (03): : 79 - 85
  • [24] Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway
    Chen, Zhiguang
    Xue, Jinqi
    Shen, Tao
    Mu, Shuai
    Fu, Qin
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 37 (02) : 329 - 338
  • [25] Glucocorticoid-induced osteoporosis
    Clowes, JA
    Peel, N
    Eastell, R
    CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (04) : 326 - 332
  • [26] Glucocorticoid-Induced Osteoporosis
    Weinstein R.S.
    Reviews in Endocrine and Metabolic Disorders, 2001, 2 (1) : 65 - 73
  • [27] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    LUKERT, BP
    SOUTHERN MEDICAL JOURNAL, 1992, 85 (08) : 2S48 - 2S51
  • [28] Glucocorticoid-induced osteoporosis
    Adachi, JD
    Ioannidis, G
    DRUG DEVELOPMENT RESEARCH, 2000, 49 (03) : 120 - 134
  • [29] Glucocorticoid-Induced Osteoporosis
    Frenkel, Baruch
    White, Wendy
    Tuckermann, Jan
    GLUCOCORTICOID SIGNALING: FROM MOLECULES TO MICE TO MAN, 2015, 872 : 179 - 215
  • [30] GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    HAHN, BH
    HOSPITAL PRACTICE, 1995, 30 (08): : 45 - &